About Ablexis
Ablexis is a Healthcare company based in San Francisco (United States) founded in 2009, and was acquired by Deerfield in June 2018. Transgenic mouse platforms are developed for human antibody discovery. Ablexis has raised $12 million across 1 funding round from investors including Third Rock Ventures, Pfizer Venture Investments and Deerfield. Its Indian entity Ironsource India Private Limited reported revenue of ₹21.75 Cr. Ablexis offers products and services including Transgenic Mouse Platform. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Ablexis was founded in 2009 in San Francisco, United States, within the biotechnology sector focused on antibody development. Transgenic mouse platforms are created by the company to support human antibody drug discovery and development. The AlivaMab Mouse platform was acquired from Aliva Biopharmaceuticals, featuring immunoglobulin loci designed for efficient function in these processes. In 2010, a consortium was formed, licensing the technology to five leading global biopharmaceutical firms, including Pfizer.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website ablexis.com
- Social X
- Acquired by Deerfield (Jun 2018)
- Legal Name Ablexis, Llc
- Date of Incorporation 26 Apr, 2016
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹21.75 Cr
FY 2025 · +206% YoY
- Indian entity net profit₹3.79 Cr
FY 2025 · 17% margin
- Indian entity EBITDA₹5.88 Cr
FY 2025 · 27% margin
- Total Equity Funding$12M (USD)
in 1 rounds
- Latest Funding Round$12M (USD), Series A
Jun 2010
- InvestorsThird Rock Ventures
& 2 more
- Acquired byDeerfield
(Jun 2018)
Associated legal entities of Ablexis
Ablexis operates through Ironsource India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ironsource India Private Limited CIN U74300KA2016FTC092539 | Active | 26 Apr 2016 | Bangalore, Karnataka | ₹21.7 Cr | 21 | 4 | View details |
Products & Services of Ablexis
Ablexis offers a comprehensive portfolio of products and services, including Transgenic Mouse Platform.
Platform for discovering and developing therapeutic antibody candidates efficiently.
Funding Insights of Ablexis
Ablexis has successfully raised a total of $12M through 1 strategic funding round. The most recent funding activity was a Series A round of $12 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12M
- Total Rounds 1
- Last Round Series A — $12M
- First Round $12M
(Jun 2010)
- Investors Count 2
All 1 funding rounds of Ablexis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2010 | $12M | Series A | – | Third Rock Ventures |
3 investors in total: 3 institutional.
Investors in Ablexis
Ablexis has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Third Rock Ventures, Pfizer Venture Investments and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States |
Investor details for Ablexis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Ironsource India Private Limited (Ablexis)
Ironsource India Private Limited is the primary company behind Ablexis. The board of Ironsource India Private Limited currently have 4 directors; the longest-serving is Nora Sen Go, appointed in 2024. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nora Sen Go DIN 10531941 | Director | 04 Mar 2024 | 2 yrs 8 mo | Ironsource India Private Limited |
| Bhagavant Bedi DIN 08005696 | Director | 21 Nov 2024 | 1 yr 11 mo | Ironsource India Private Limited |
| Jasmine De Layton DIN 10792925 | Director | 08 Jul 2025 | 1 yr 4 mo | Ironsource India Private Limited |
| Shridhar Subbaraman Iyer DIN 07151577 | Director | 30 Oct 2025 | 1 yr | Ironsource India Private Limited |
People of Ablexis
1 people are tracked at Ablexis (1 in leadership).
| Name | Role | Group |
|---|---|---|
Larry Green | Founder & CEO | Leadership |
Complete people profiles for Ablexis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Ablexis
Figures of Ironsource India Private Limited, the primary company behind Ablexis, for FY 2025. Revenue was ₹21.75 Cr (+206% year on year). Net profit was ₹3.79 Cr (17% margin). EBITDA was ₹5.88 Cr (27% margin). Revenue has grown at a compounded annual rate of +87% over three years and +59% over five years.
- ₹21.75 CrRevenue · FY 2025 · +206% YoY
- ₹3.79 CrNet profit · 17% margin
- ₹5.88 CrEBITDA · 27% margin
- ₹1 LakhPaid-up capital
- 21Employees (provident fund records)
- +87%Revenue CAGR, 3 years
- +59%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Ironsource India Private Limited are on its company page.
Detailed financial statements for Ablexis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ablexis
3 dated milestones of Ablexis across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Ablexis is founded.
- Funding First funding round of $12.0M.
- Exit Acquired by Deerfield.
Competitors of Ablexis
Ablexis has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Ablexis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ablexis
The website of Ablexis (ablexis.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▲ 18% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Ablexis (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ablexis
Complete news archive for Ablexis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ablexis
Ablexis was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Ablexis is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Ablexis is a funded company, having raised a total of $12M across 1 funding round to date. The company's 1st funding round was a Series A of $12M, raised on Jun 2010.
The primary company behind Ablexis, Ironsource India Private Limited, reported revenue of ₹21.75 Cr for FY 2025, up 206% year on year.
Ablexis was founded in 2009 in San Francisco, United States, within the biotechnology sector focused on antibody development. Transgenic mouse platforms are created by the company to support human antibody drug discovery and development. The AlivaMab Mouse platform was acquired from Aliva Biopharmaceuticals, featuring immunoglobulin loci designed for efficient function in these processes. In 2010, a consortium was formed, licensing the technology to five leading global biopharmaceutical firms, including Pfizer.
Ablexis's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Ablexis offers Transgenic Mouse Platform.
Ablexis has 3 investors. Key investors include Third Rock Ventures, Pfizer Venture Investments, and Deerfield.
Ablexis operates through Ironsource India Private Limited.
Yes. Ablexis was acquired by Deerfield in June 2018.
The legal entities of Ablexis currently have 4 directors, including Nora Sen Go, Bhagavant Bedi, Shridhar Subbaraman Iyer and others.